Skip to main content
PMC home page
Gut logoLink to Gut
. 2001 Jan;48(1):103–109. doi: 10.1136/gut.48.1.103

Hepatocellular carcinoma in Central Europe: prognostic features and survival

M Schoniger-Hekele 1, C Muller 1, M Kutilek 1, C Oesterreicher 1, P Ferenci 1, A Gangl 1
PMCID: PMC1728163  PMID: 11115830

Abstract

BACKGROUND AND AIMS—We investigated the influence of baseline characteristics of patients with hepatocellular carcinoma (HCC) on prognosis and developed a multivariate Cox model predicting survival. All patients were from Central Europe.
METHODS—All 245 patients seen at the Department of Gastroenterology and Hepatology at the University of Vienna, Austria, from July 1991 to March 1998 were included in this retrospective study. Nineteen different clinical characteristics and survival time from date of diagnosis were noted. Factors determining survival time were analysed by univariate and multivariate analysis using Cox proportional hazard regression models and a new classification model was constructed. The validity of this model was tested on an independent group of 89 patients, seen from April 1998 to September 1999.
RESULTS—Median survival in patients with HCC was 8.0 months. In a multivariate analysis bilirubin (>2 mg/dl), portal vein thrombosis, prothrombin time (<70%), alpha fetoprotein (>180 µg/l), tumour mass >50%, and enlarged lymph nodes were independent predictors of survival. A newly constructed Cox proportional hazard model (Vienna survival model for HCC=VISUM-HCC) identified three disease stages with different durations of survival (median survival stage 1, 15.2 months; stage 2, 7.2 months; and stage 3, 2.6 months; p=0.00001). Applying the VISUM-HCC survival model to patients in Okuda stage 2 identified subgroups with an excellent and very poor prognosis for which different treatment modalities should be offered.
CONCLUSIONS—Our patients with HCC had a poor median survival of eight months. Six easily measurable clinical variables were significant predictors of survival in patients with HCC. The new VISUM-HCC survival model may be useful for stratifying patients with HCC for various clinical treatment modalities.


Keywords: hepatocellular carcinoma; clinical presentation; prognostic model

Full Text

The Full Text of this article is available as a PDF (183.8 KB).

Figure 1  .

Figure 1  

Open in a new tab

(A) Cumulative survival rate for all 245 patients included in the study. Median survival was 8.0 months. (B) Cumulative survival of patients with hepatocellular carcinoma with cirrhosis Child stage A (n=84), Child stage B (n=93), and Child stage C (n=35), and without liver cirrhosis (No LC) (n=33). Survival was significantly different between patients with and without cirrhosis (log rank test, p=0.00041).

Figure 2  .

Figure 2  

Open in a new tab

(A) Cumulative survival of patients with hepatocellular carcinoma (HCC) (n=245) grouped according to Okuda stages: stage 1 (n=40), stage 2 (n=161), and stage 3 (n=44). Survival was statistically different between stages 2 and 3 (log rank test, p=0.0001) but not between stages 1 and 2 (log rank test, p=0.06331). (B) Cumulative survival rate of patients grouped according to the newly developed staging system VISUM-HCC, incorporating the six significant predictive variables (bilirubin >2 mg/dl, prothrombin time <70%, portal vein thrombosis, tumour mass >50%, enlarged lymph nodes, α fetoprotein >125 kU/l), as determined by multivariate analysis.

Figure 3  .

Figure 3  

Open in a new tab

Survival curves of patients stratified according to VISUM-HCC criteria between the model group (group A) and the testing group (group B); no significant difference was found.

Figure 4  .

Figure 4  

Open in a new tab

(A) Okuda stage 2, (B) Okuda stage 2 grouped according to VISUM-HCC; significantly different survival rates were noted between stages 1, 2, and 3. 

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akashi Y., Koreeda C., Enomoto S., Uchiyama S., Mizuno T., Shiozaki Y., Sameshima Y., Inoue K. Prognosis of unresectable hepatocellular carcinoma: an evaluation based on multivariate analysis of 90 cases. Hepatology. 1991 Aug;14(2):262–268. [PubMed] [Google Scholar]
  2. Bianchi P., Porro C. B., Coltorti M., Dardanoni L., Del Vecchio Blanco C., Fagiolo U., Farini R., Menozzi I., Naccarato R., Pagliaro L. Occurrence of Australia antigen in chronic hepatitis in Italy. Gastroenterology. 1972 Sep;63(3):482–485. [PubMed] [Google Scholar]
  3. Bismuth H., Morino M., Sherlock D., Castaing D., Miglietta C., Cauquil P., Roche A. Primary treatment of hepatocellular carcinoma by arterial chemoembolization. Am J Surg. 1992 Apr;163(4):387–394. doi: 10.1016/0002-9610(92)90039-t. [DOI] [PubMed] [Google Scholar]
  4. Bruix J. Treatment of hepatocellular carcinoma. Hepatology. 1997 Feb;25(2):259–262. doi: 10.1053/jhep.1997.v25.ajhep0250259. [DOI] [PubMed] [Google Scholar]
  5. Calvet X., Bruix J., Ginés P., Bru C., Solé M., Vilana R., Rodés J. Prognostic factors of hepatocellular carcinoma in the west: a multivariate analysis in 206 patients. Hepatology. 1990 Oct;12(4 Pt 1):753–760. doi: 10.1002/hep.1840120422. [DOI] [PubMed] [Google Scholar]
  6. Chevret S., Trinchet J. C., Mathieu D., Rached A. A., Beaugrand M., Chastang C. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. J Hepatol. 1999 Jul;31(1):133–141. doi: 10.1016/s0168-8278(99)80173-1. [DOI] [PubMed] [Google Scholar]
  7. Christensen E. Multivariate survival analysis using Cox's regression model. Hepatology. 1987 Nov-Dec;7(6):1346–1358. doi: 10.1002/hep.1840070628. [DOI] [PubMed] [Google Scholar]
  8. Collier J. D., Curless R., Bassendine M. F., James O. F. Clinical features and prognosis of hepatocellular carcinoma in Britain in relation to age. Age Ageing. 1994 Jan;23(1):22–27. doi: 10.1093/ageing/23.1.22. [DOI] [PubMed] [Google Scholar]
  9. Collier J. D., Curless R., Bassendine M. F., James O. F. Clinical features and prognosis of hepatocellular carcinoma in Britain in relation to age. Age Ageing. 1994 Jan;23(1):22–27. doi: 10.1093/ageing/23.1.22. [DOI] [PubMed] [Google Scholar]
  10. Colombo M., de Franchis R., Del Ninno E., Sangiovanni A., De Fazio C., Tommasini M., Donato M. F., Piva A., Di Carlo V., Dioguardi N. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med. 1991 Sep 5;325(10):675–680. doi: 10.1056/NEJM199109053251002. [DOI] [PubMed] [Google Scholar]
  11. Di Bisceglie A. M., Rustgi V. K., Hoofnagle J. H., Dusheiko G. M., Lotze M. T. NIH conference. Hepatocellular carcinoma. Ann Intern Med. 1988 Mar;108(3):390–401. doi: 10.7326/0003-4819-108-3-390. [DOI] [PubMed] [Google Scholar]
  12. Dorfman R. E., Alpern M. B., Gross B. H., Sandler M. A. Upper abdominal lymph nodes: criteria for normal size determined with CT. Radiology. 1991 Aug;180(2):319–322. doi: 10.1148/radiology.180.2.2068292. [DOI] [PubMed] [Google Scholar]
  13. Dusheiko G. M., Hobbs K. E., Dick R., Burroughs A. K. Treatment of small hepatocellular carcinomas. Lancet. 1992 Aug 1;340(8814):285–288. doi: 10.1016/0140-6736(92)92367-o. [DOI] [PubMed] [Google Scholar]
  14. EDMONDSON H. A., STEINER P. E. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954 May;7(3):462–503. doi: 10.1002/1097-0142(195405)7:3<462::aid-cncr2820070308>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  15. El-Serag H. B., Mason A. C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999 Mar 11;340(10):745–750. doi: 10.1056/NEJM199903113401001. [DOI] [PubMed] [Google Scholar]
  16. Falkson G., Cnaan A., Schutt A. J., Ryan L. M., Falkson H. C. Prognostic factors for survival in hepatocellular carcinoma. Cancer Res. 1988 Dec 15;48(24 Pt 1):7314–7318. [PubMed] [Google Scholar]
  17. Ginés P., Quintero E., Arroyo V., Terés J., Bruguera M., Rimola A., Caballería J., Rodés J., Rozman C. Compensated cirrhosis: natural history and prognostic factors. Hepatology. 1987 Jan-Feb;7(1):122–128. doi: 10.1002/hep.1840070124. [DOI] [PubMed] [Google Scholar]
  18. Iwatsuki S., Starzl T. E., Sheahan D. G., Yokoyama I., Demetris A. J., Todo S., Tzakis A. G., Van Thiel D. H., Carr B., Selby R. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg. 1991 Sep;214(3):221–229. doi: 10.1097/00000658-199109000-00005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Izumi R., Shimizu K., Ii T., Yagi M., Matsui O., Nonomura A., Miyazaki I. Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection. Gastroenterology. 1994 Mar;106(3):720–727. doi: 10.1016/0016-5085(94)90707-2. [DOI] [PubMed] [Google Scholar]
  20. Llovet J. M., Brú C., Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(3):329–338. doi: 10.1055/s-2007-1007122. [DOI] [PubMed] [Google Scholar]
  21. Lunn R. M., Zhang Y. J., Wang L. Y., Chen C. J., Lee P. H., Lee C. S., Tsai W. Y., Santella R. M. p53 mutations, chronic hepatitis B virus infection, and aflatoxin exposure in hepatocellular carcinoma in Taiwan. Cancer Res. 1997 Aug 15;57(16):3471–3477. [PubMed] [Google Scholar]
  22. Montesano R., Hainaut P., Wild C. P. Hepatocellular carcinoma: from gene to public health. J Natl Cancer Inst. 1997 Dec 17;89(24):1844–1851. doi: 10.1093/jnci/89.24.1844. [DOI] [PubMed] [Google Scholar]
  23. Mor E., Tur-Kaspa R., Sheiner P., Schwartz M. Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation. Ann Intern Med. 1998 Oct 15;129(8):643–653. doi: 10.7326/0003-4819-129-8-199810150-00013. [DOI] [PubMed] [Google Scholar]
  24. Nomura F., Ohnishi K., Tanabe Y. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients. Cancer. 1989 Oct 15;64(8):1700–1707. doi: 10.1002/1097-0142(19891015)64:8<1700::aid-cncr2820640824>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  25. Okada S., Okazaki N., Nose H., Yoshimori M., Aoki K. Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. Hepatology. 1992 Jul;16(1):112–117. doi: 10.1002/hep.1840160119. [DOI] [PubMed] [Google Scholar]
  26. Okuda K., Ohtsuki T., Obata H., Tomimatsu M., Okazaki N., Hasegawa H., Nakajima Y., Ohnishi K. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985 Aug 15;56(4):918–928. doi: 10.1002/1097-0142(19850815)56:4<918::aid-cncr2820560437>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  27. Paterlini P., Driss F., Nalpas B., Pisi E., Franco D., Berthelot P., Bréchot C. Persistence of hepatitis B and hepatitis C viral genomes in primary liver cancers from HBsAg-negative patients: a study of a low-endemic area. Hepatology. 1993 Jan;17(1):20–29. [PubMed] [Google Scholar]
  28. Pawarode A., Voravud N., Sriuranpong V., Kullavanijaya P., Patt Y. Z. Natural history of untreated primary hepatocellular carcinoma: a retrospective study of 157 patients. Am J Clin Oncol. 1998 Aug;21(4):386–391. doi: 10.1097/00000421-199808000-00014. [DOI] [PubMed] [Google Scholar]
  29. Petry W., Heintges T., Hensel F., Erhardt A., Wenning M., Niederau C., Häussinger D. Hepatozelluläres Karzinom in Deutschland. Epidemiologie, Atiologie, Klinik und Prognose bei 100 konsekutiven Patienten einer Universitätsklinik. Z Gastroenterol. 1997 Dec;35(12):1059–1067. [PubMed] [Google Scholar]
  30. Ringe B., Pichlmayr R., Wittekind C., Tusch G. Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg. 1991 Mar-Apr;15(2):270–285. doi: 10.1007/BF01659064. [DOI] [PubMed] [Google Scholar]
  31. Simonetti R. G., Cammà C., Fiorello F., Politi F., D'Amico G., Pagliaro L. Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci. 1991 Jul;36(7):962–972. doi: 10.1007/BF01297149. [DOI] [PubMed] [Google Scholar]
  32. Stroffolini T., Andreone P., Andriulli A., Ascione A., Craxi A., Chiaramonte M., Galante D., Manghisi O. G., Mazzanti R., Medaglia C. Characteristics of hepatocellular carcinoma in Italy. J Hepatol. 1998 Dec;29(6):944–952. doi: 10.1016/s0168-8278(98)80122-0. [DOI] [PubMed] [Google Scholar]
  33. Stuart K. E., Anand A. J., Jenkins R. L. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer. 1996 Jun 1;77(11):2217–2222. doi: 10.1002/(SICI)1097-0142(19960601)77:11<2217::AID-CNCR6>3.0.CO;2-M. [DOI] [PubMed] [Google Scholar]
  34. Stuart K., Stokes K., Jenkins R., Trey C., Clouse M. Treatment of hepatocellular carcinoma using doxorubicin/ethiodized oil/gelatin powder chemoembolization. Cancer. 1993 Dec 1;72(11):3202–3209. doi: 10.1002/1097-0142(19931201)72:11<3202::aid-cncr2820721112>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  35. Tang Z. Y. Treatment of hepatocellular carcinoma. Digestion. 1998 Aug;59(5):556–562. doi: 10.1159/000007531. [DOI] [PubMed] [Google Scholar]
  36. Trinchet J. C., Beaugrand M. Treatment of hepatocellular carcinoma in patients with cirrhosis. J Hepatol. 1997 Oct;27(4):756–765. doi: 10.1016/s0168-8278(97)80095-5. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES